Skip to main content
TipRanks
Go Ultimate75% OFF

Galectin Therapeutics (GALT) Stock Statistics & Valuation Metrics

683 Followers

Total Valuation

Galectin Therapeutics has a market cap or net worth of $307.59M. The enterprise value is $432.36M.

Market Cap
$307.59M
Enterprise Value
$432.36M

Share Statistics

Galectin Therapeutics has 100,849,650 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
100,849,650
Owned by Insiders
51.09%
Owned by Institutions
13.03%

Financial Efficiency

Galectin Therapeutics’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is -174.29%.

Return on Equity (ROE)
0.24
Return on Assets (ROA)
-1.58
Return on Invested Capital (ROIC)
-174.29%
Return on Capital Employed (ROCE)
-1.75
Revenue Per Employee
0
Profits Per Employee
-3.43M
Employee Count
9
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Galectin Therapeutics is -7.14. Galectin Therapeutics’s PEG ratio is -0.18.

PE Ratio
-7.14
PS Ratio
0.00
PB Ratio
-1.47
Price to FCF
-12.64
Price to Operating Cash Flow
-12.65
PEG Ratio
-0.18

Income Statement

In the last 12 months, Galectin Therapeutics had revenue of 0 and earned -30.84M in profits. Earnings per share was -0.48.

Revenue
0
Gross Profit
0
Operating Income
-20.09M
Pretax Income
-30.84M
Net Income
-30.84M
EBITDA
-23.45M
Earnings Per Share (EPS)
-0.48

Cash Flow

In the last 12 months, operating cash flow was -15.89M and capital expenditures 0, giving a free cash flow of -15.89M billion.

Operating Cash Flow
-15.89M
Free Cash Flow
-15.89M
Free Cash Flow per Share
-0.24

Dividends & Yields

Galectin Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-7.91%
Earnings Yield
-13.86%

Stock Price Statistics

Beta
0.15
52-Week Price Change
-44.85%
50-Day Moving Average
3.68
200-Day Moving Average
3.23
Relative Strength Index (RSI)
39.58
Average Volume (3m)
256.39K

Important Dates

Galectin Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 14, 2026
Next Earnings Date
Nov 16, 2026
Ex-Dividend Date
―

Financial Position

Galectin Therapeutics as a current ratio of 2.42, with Debt / Equity ratio of -105.99%

Current Ratio
2.42
Quick Ratio
2.42
Debt to Market Cap
0.50
Net Debt to EBITDA
-4.95
Interest Coverage Ratio
-2.74

Taxes

In the past 12 months, Galectin Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Galectin Therapeutics EV to EBITDA ratio is -23.65, with an EV/FCF ratio of -20.47.

EV to Sales
0.00
EV to EBITDA
-23.65
EV to Free Cash Flow
-20.47
EV to Operating Cash Flow
-20.47

Balance Sheet

Galectin Therapeutics has $13.27M in cash and marketable securities with $137.70M in debt, giving a net cash position of -$124.43M billion.

Cash & Marketable Securities
$13.27M
Total Debt
$137.70M
Net Cash
-$124.43M
Net Cash Per Share
-$1.23
Tangible Book Value Per Share
-$2.08

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Galectin Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$11.00
Price Target Upside
260.66% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
33.25%

Scores

Smart Score
5
AI Score
46